Borui Pharmaceutical announced that in the first half of 2026, the company had no major irregularities and invested 249.37910,000 yuan in R&D, accounting for 36.78% of revenue. The company has risks such as innovative drug research and development, talent team building, performance fluctuations, product substitution, drug quality control, production safety, tax preferential policy changes, industry policy adjustments, and exchange rate fluctuations. The storage and use of funds raised by the company complies with relevant regulations, and there are no cases of illegal use.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.